Efficacy and Safety of Selinexor for Heavily Pretreated Multiple Myeloma Treatment – A Systematic Review

Tariq, Muhammad Junaid; Farooqui, Arafat Ali; Faisal, Muhammad Salman; Farooqi, Muhammad Saad; Shaukat, Tanveer; Anjum, Ahmad; Rehman, Saifur; Ullah, Muhammad Qudrat; Bajwa, Hamza; Anwer, Faiz

doi:10.1016/j.clml.2019.09.200

Cited by 1 publication

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite the promising preclinical findings, the addition of doxorubicin to Sd did not improve the ORR (ORR at 15%), despite being well tolerated, in a multicenter, openlabel phase I/II clinical trial (NCT02186834). 40,41 Selinexor After Previous Treatment with Cellular Therapies…”

Section: Selinexor-doxorubicin-dexamethasonementioning

confidence: 99%

<p>Clinical Utility of Selinexor/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma: A Review of Current Evidence and Patient Selection</p>

Malandrakis

Ntanasis‐Stathopoulos

Gavriatopoulou

et al. 2020

OTT

View full text Add to dashboard Cite

Multiple myeloma (MM) is one the most common hematological malignancies, and despite the survival prolongation offered by proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs) and anti-CD38 monoclonal antibodies, the need for novel agents is prominent. Selinexor is a first-in-class, oral, selective inhibitor of exportin-1 (XPO1), a vital protein for the exportation of more than 200 tumor suppressor proteins from the nucleus. Both in solid tumors and hematologic malignancies, selinexor-mediated inhibition of nucleus export seems to effectively lead to cancer cell death. Selinexor in combination with dexamethasone (Sd) received an accelerated FDA approval on July 2019 for heavily pretreated patients with relapsed/refractory MM (RRMM) based on the promising results of the Phase II STORM trial. The preliminary results of the randomized Phase III BOSTON trial have shown a 47% increase in progression-free survival among PI-sensitive, RRMM patients who received selinexor with bortezomib-dexamethasone compared with bortezomib-dexamethasone alone. Several different selinexor-containing triplet regimens are currently being tested in the RRMM setting in an umbrella trial, and the preliminary results seem promising. Furthermore, the addition of selinexor in other anti-myeloma agents seems to overcome drug-acquired resistance in preclinical studies. The main toxicities of selinexor are gastrointestinal disorders and hematologic toxicities (mainly thrombocytopenia); however, they are manageable with proper supportive measures. In conclusion, selinexor is a new anti-myeloma drug that seems to be effective in patients who have no other therapeutic options, including patients who have received novel cellular therapies such as CART cells. Its potential role earlier in the therapeutic algorithm of MM is currently under clinical investigation.

show abstract

Section: Selinexor-doxorubicin-dexamethasonementioning

confidence: 99%